Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics

R. Kucera, O. Topolcan, I. Treskova, J. Kinkorova, J. Windrichova, R. Fuchsova, S. Svobodova, V. Treska, V. Babuska, J. Novak, J. Smejkal,

. 2015 ; 35 (6) : 3537-41.

Language English Country Greece

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15031335

AIM: The aim of the present study was to evaluate the usefulness of four interleukins (IL-2, IL-6, IL-8 and IL-10) for melanoma detection and correlate these interleukins with sentinel node metastasis positivity. PATIENTS AND METHODS: A group of 236 persons was assessed: 175 patients with melanomas and 61 healthy persons. Melanoma patients were divided to four groups according to Breslow score. We determined IL-2, IL-6, IL-8 and IL-10 in each plasma sample. Interleukin plasma levels were assayed using a Human Cytokine Milliplex Map kit. Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader. Plasma samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. RESULTS: We compared interleukin plasma levels in the healthy group and plasma levels in each Breslow score stage. In the first Breslow score stage, IL-2 (p<0.0001), IL-6 (p=0.0004) and IL-10 (p<0.0001) were positive. In the second Breslow score, stage IL-2 (p<0.0001), IL-6 (p<0.0001), IL-8 (p=0.0017) and IL-10 (p<0.0001) were positive. By comparing the group of positive and negative sentinel node metastasis, we observed a statistically significant difference in two interleukins: The median of IL-2 levels in the negative group was 5.88 pg/ml compared to 32.57 pg/ml in the positive group (p=0.0005). The median of IL-6 levels in the negative group was 4.80 pg/ml compared to 32.02 pg/ml in the positive group (p=0.0048). CONCLUSION: Interleukins IL-2, IL-6 and IL-10 are promising biomarkers of early-stage melanoma. IL-2 and IL-6 appear to be prognostic biomarkers.

000      
00000naa a2200000 a 4500
001      
bmc15031335
003      
CZ-PrNML
005      
20200720082508.0
007      
ta
008      
151005s2015 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)26026122
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kucera, Radek $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
245    10
$a Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics / $c R. Kucera, O. Topolcan, I. Treskova, J. Kinkorova, J. Windrichova, R. Fuchsova, S. Svobodova, V. Treska, V. Babuska, J. Novak, J. Smejkal,
520    9_
$a AIM: The aim of the present study was to evaluate the usefulness of four interleukins (IL-2, IL-6, IL-8 and IL-10) for melanoma detection and correlate these interleukins with sentinel node metastasis positivity. PATIENTS AND METHODS: A group of 236 persons was assessed: 175 patients with melanomas and 61 healthy persons. Melanoma patients were divided to four groups according to Breslow score. We determined IL-2, IL-6, IL-8 and IL-10 in each plasma sample. Interleukin plasma levels were assayed using a Human Cytokine Milliplex Map kit. Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader. Plasma samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. RESULTS: We compared interleukin plasma levels in the healthy group and plasma levels in each Breslow score stage. In the first Breslow score stage, IL-2 (p<0.0001), IL-6 (p=0.0004) and IL-10 (p<0.0001) were positive. In the second Breslow score, stage IL-2 (p<0.0001), IL-6 (p<0.0001), IL-8 (p=0.0017) and IL-10 (p<0.0001) were positive. By comparing the group of positive and negative sentinel node metastasis, we observed a statistically significant difference in two interleukins: The median of IL-2 levels in the negative group was 5.88 pg/ml compared to 32.57 pg/ml in the positive group (p=0.0005). The median of IL-6 levels in the negative group was 4.80 pg/ml compared to 32.02 pg/ml in the positive group (p=0.0048). CONCLUSION: Interleukins IL-2, IL-6 and IL-10 are promising biomarkers of early-stage melanoma. IL-2 and IL-6 appear to be prognostic biomarkers.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-10 $x krev $7 D016753
650    _2
$a interleukin-2 $x krev $7 D007376
650    _2
$a interleukin-6 $x krev $7 D015850
650    _2
$a interleukin-8 $x krev $7 D016209
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x krev $x patologie $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a biopsie sentinelové lymfatické uzliny $7 D021701
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Topolcan, Ondrej $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Treskova, Inka $u Department of Plastic Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kinkorová, Judita, $d 1960- $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic kinkorovaj@fnplzen.cz. $7 xx0001268
700    1_
$a Windrichová, Jindra $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic. $7 xx0209887
700    1_
$a Fuchsova, Radka $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Svobodova, Sarka $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Treska, Vladislav $u Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Babuska, Vaclav $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Novak, Jaroslav $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Smejkal, Jiri $u Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 6 (2015), s. 3537-41
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26026122 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20200720082508 $b ABA008
999    __
$a ok $b bmc $g 1092211 $s 914461
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 35 $c 6 $d 3537-41 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Archiving options